IPSC - Latest News
Century Therapeutics, Inc. (IPSC), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $197.4M. Beta to the broader market is 1.56.
The article list below shows the most recent IPSC headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent IPSC Headlines
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
globenewswire.com - May 14, 2026
NORWOOD, Mass. , May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc.
Century Therapeutics Reports First Quarter Financial Results and Business Updates
globenewswire.com - May 13, 2026
PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluri
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
globenewswire.com - Apr 30, 2026
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5. 0 for patients with type 1 diabetes; on track for IND subm
Century Therapeutics: A Biotech With Interesting Optionality Opportunities
seekingalpha.com - Apr 24, 2026
Century Therapeutics earns a speculative Buy rating, with a 10-15% upside and right-skewed return potential for risk-tolerant investors. IPSC pivoted
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $3.80
defenseworld.net - Mar 5, 2026
Shares of Century Therapeutics, Inc. (NASDAQ: IPSC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight resear
How News Affects IPSC Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IPSC's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked IPSC news questions
- What is the latest IPSC news headline?
- The most recent IPSC headline (May 14, 2026) is "Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the IPSC news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What IPSC news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual IPSC options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.